Shaheen Kavoussi, MD
Ophthalmology · Houston, TXNPI 1063788446
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $325,430 of the $480,396 with a category attached, or 67.7%. Regeneron Healthcare Solutions, Inc. accounts for 62.4% of it on its own, with 21 other manufacturers making up the rest. Among ophthalmology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 611 payments — averaging $786.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$300K
- AbbVie$81K
- Heidelberg Engineering, Inc.$72K
- Regeneron$13K
- Iridex Corporation$8K
- Alimera Sciences, Inc.$2K
- plus $4K from 16 others
Across 42 payments — averaging $19,889 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ocular Therapeutix, Inc.$636K
- Alcon Research LLC$110K
- AbbVie$89K
What the payments were for
- Consulting fees$82,77317%
- Speaking & faculty fees$325,43068%
- Travel & lodging$57,04712%
- Food & beverage$14,8433%
- Education$2940%
- Gifts$100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 378 | $299,723 |
| AbbVie(2 entities) | 137 | $81,490 |
| Heidelberg Engineering, Inc. | 7 | $72,434 |
| Regeneron | 22 | $12,848 |
| Iridex Corporation | 3 | $7,569 |
| Alimera Sciences, Inc. | 18 | $2,279 |
| Ocular Therapeutix, Inc. | 9 | $2,179 |
| Genentech USA, Inc. | 10 | $451 |
| Astellas Pharma US Inc | 4 | $346 |
| Novartis | 2 | $224 |
| Apellis Pharmaceuticals, Inc. | 4 | $184 |
| Bausch & Lomb Americas Inc. | 3 | $181 |
| Eyepoint US, Inc. | 2 | $139 |
| Aerie Pharmaceuticals, Inc. | 1 | $115 |
| Harrow Eye, LLC | 2 | $58 |
| Sun Pharmaceutical Industries Inc. | 2 | $40 |
| Samsara Vision | 1 | $32 |
| ANI Pharmaceuticals, Inc. | 1 | $30 |
| Genentech, Inc. | 2 | $29 |
| Mallinckrodt Enterprises LLC | 1 | $24 |
| Alcon | 1 | $14 |
| Oculus Surgical Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$480,396 in reported general payments places this provider in the 95th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 138 | $5,480 |
| MoxifloxacinMoxifloxacin Hcl | 81 | $2,627 |
| Ketorolac Tromethamine | 60 | $929 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 33 | $498 |
| Latanoprost | 28 | $299 |
| Brimonidine Tartrate | 34 | $199 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Houston
- John MichelettiHouston$916K
- Christina WengHouston$676K
- Peter ChangHouston$656K
- Zaina Al-MohtasebHouston$636K
- Stephen SladeHouston$530K
- David BrownHouston$514K
- Elvia CansecoHouston$322K
- Bac NguyenHouston$319K
- Douglas KochHouston$308K
- Rahul PanditHouston$289K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.